CYSTEINPROTEASE

European patent · EP3256579 · In force

Register entry

Publication number
EP3256579
Application number
EP16704223
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Feb 12, 2016
Published
Dec 20, 2017
Granted
Aug 30, 2023
Protection ends at the latest
Feb 11, 2036
Next annual fee due
Feb 28, 2027
IPC classes
C12N 9/24 (2006.01)
Priority
GB 201502305 12.02.2015
PCT application
PCT/EP2016/053054 12.02.2016
PCT publication
WO2016/128559 18.08.2016
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Mar 1, 2026

    Change

    Published in Swissreg on 01.03.2026

  2. Mar 1, 2025

    Change

    Published in Swissreg on 01.03.2025

  3. Jul 10, 2024

    Change

    Published in Swissreg on 10.07.2024

  4. Mar 1, 2024

    Change

    Published in Swissreg on 01.03.2024

  5. Nov 8, 2023

    Agent entered

    Representative
    Isler & Pedrazzini AG, Postfach, 8027 Zürich

    Published in Swissreg on 08.11.2023

  6. Aug 30, 2023

    Granted

    Published in Swissreg on 30.08.2023

Parties

Holder

Hansa Biopharma AB

Box 785, 220 07 Lund, SE

Agent

Isler & Pedrazzini AG

Postfach, 8027 Zürich

Inventor

JARNUM, Sofia

220 07 Lund, SE

KJELLMAN, Christian

220 07 Lund, SE

NORDAHL, Emma

220 07 Lund, SE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.